The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy. The use of selective internal radiotherapy treatment (SIRT-Y90) is proven efficacious in patients with intra-heptic tumor. Previous experience with SIRT is safe in patients with intrahepatic cholangiocarcinoma. This study aims to study the benefits of sequential administration of SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histological or cytological diagnosis of cholangiocarcinoma
Disease not amenable to surgery
Predominant disease load in the liver (in case of extra-hepatic involvement, only patients with lymph nodes metastases are allowed)
Naïve to locoregional or systemic treatment (but patients who develop recurrent disease after surgery are suitable)
ECOG PS 0-1
At least one measurable disease lesion according to RECIST v 1.1
Life expectancy of 12 weeks or longer
Adequate hematological, renal and hepatic function
Platelet ≥100 x 109
ANC ≥ 1.5 x 109
Bilirubin ≤ 30µmol/L
Albumin ≥ 30g/L
ALT ≤ 3 ULN
INR ≤ 1.5
Serum creatinine ≤ 1.5 x ULN
Prior malignancy except cervical carcinoma-in-situ or treated basal cell carcinoma. Any cancers treated curatively > 5 years prior to study entry are permitted.
Patients with extra-hepatic disease other than regional lymph node metastases.
Evidence of ascites or cirrhosis, as determined by clinical or radiologic assessment
Biliary obstruction with no possibility of drainage
Non-malignant disease that would render the patient unsuitable for treatment according to the protocol
Prior treatment of chemotherapy for the cholangiocarcinoma